Dr. Ali Khaki on managing toxicities with enfortumab vedotin for bladder cancer
Ali Raza Khaki, MD, genitourinary specialist, clinical assistant professor, Medicine – Oncology, Stanford Medicine, discusses managing toxicities to ensure patients can continue to receive treatment with the antibody-drug conjugate enfortumab vedotin-ejfv (Padcev). Khaki shared this information with his colleagues at a recent clinical workshop.
Enfortumab vedotin is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy; or patients who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
